The additive effect of Eldecalcitol for glucocorticoid induced osteoporosis responding poorly to Alendronate.
Not Applicable
- Conditions
- glucocorticoid induced osteoporosis
- Registration Number
- JPRN-UMIN000009586
- Lead Sponsor
- Department of Rheumatic Disease, Shinko Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with contraindication for Eldecalcitol treatments 2. Patients who are inappropriate for this study by physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change from baseline to 12 months in lumbar spine BMD
- Secondary Outcome Measures
Name Time Method Change from baseline to 12 months in total hip BMD bone turnover markers (TRACP-5b,uNTX, BAP, intact PTH, whole PTH, Sclerostin, OC, ucOC) incidence of fracture (vertebral fractures, non- vertebral fractures), blood calcium urinary calcium creatinine